M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic

Recruiting

Conditions: COVID-19 Infection
Melanoma

Interventions: Other: Survey Administration

First Posted Date: 2020-07-16

Last Posted Date: 2024-11-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1152

Registration Number: NCT04474301

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Phase 2

Completed

Conditions: Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Extranodal Marginal Zone Lymphoma

Interventions: Other: Radiation Therapy

First Posted Date: 2020-07-09

Last Posted Date: 2022-03-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 75

Registration Number: NCT04465162

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2

Recruiting

Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions: Biological: Rituximab
Drug: Zanubrutinib

First Posted Date: 2020-07-07

Last Posted Date: 2024-10-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT04458610

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors

Active, not recruiting

Conditions: COVID-19 Infection
Malignant Solid Neoplasm

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Other: Survey Administration

First Posted Date: 2020-06-25

Last Posted Date: 2024-08-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1242

Registration Number: NCT04447222

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Drug: Azacitidine
Biological: Magrolimab
Drug: Venetoclax

First Posted Date: 2020-06-17

Last Posted Date: 2024-12-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 110

Registration Number: NCT04435691

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

Phase 2

Completed

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions: Biological: Anakinra
Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2020-06-16

Last Posted Date: 2024-05-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT04432506

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study

Recruiting

Conditions: Lung Non-Small Cell Carcinoma
Stage IA3 Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8
Stage IV Colorectal Cancer AJCC v8
Metastatic Sarcoma
Stage I Lung Cancer AJCC v8
Stage IA2 Lung Cancer AJCC v8
Stage IIA Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8

Interventions: Procedure: Computed Tomography with Contrast
Procedure: Microwave Ablation
Other: Questionnaire Administration
Procedure: Wedge Excision

First Posted Date: 2020-06-12

Last Posted Date: 2024-08-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT04430725

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

Phase 1

Recruiting

Conditions: Melanoma
Malignant Genitourinary System Neoplasm
Colitis
Malignant Solid Neoplasm
Lung Non-Small Cell Carcinoma

Interventions: Biological: Infliximab
Biological: Vedolizumab

First Posted Date: 2020-05-29

Last Posted Date: 2024-12-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT04407247

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

Phase 2

Active, not recruiting

Conditions: Ann Arbor Stage III Grade 1 Follicular Lymphoma
Ann Arbor Stage III Grade 2 Follicular Lymphoma
Ann Arbor Stage III Grade 3 Follicular Lymphoma
Ann Arbor Stage IV Grade 1 Follicular Lymphoma
Ann Arbor Stage IV Grade 2 Follicular Lymphoma
Ann Arbor Stage IV Grade 3 Follicular Lymphoma
Grade 3a Follicular Lymphoma

Interventions: Drug: Acalabrutinib
Drug: Lenalidomide
Biological: Rituximab

First Posted Date: 2020-05-27

Last Posted Date: 2024-10-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT04404088

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Phase 1

Recruiting

Conditions: Castration-Resistant Prostate Carcinoma
Metastatic Malignant Solid Neoplasm
Metastatic Prostate Carcinoma
Metastatic Urothelial Carcinoma
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8
Aggressive Variant Prostate Carcinoma
Metastatic Clear Cell Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v8

Interventions: Biological: Ipilimumab
Drug: Valemetostat

First Posted Date: 2020-05-14

Last Posted Date: 2024-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT04388852

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Home Terms & Conditions Privacy Policy